XOFLUZA is an influenza virus polymerase acidic (PA) endonuclease inhibitor indicated for:
Limitations of Use
Influenza viruses change over time, and factors such as the virus type or subtype, emergence of resistance, or changes in viral virulence could diminish the clinical benefit of antiviral drugs. Consider available information on drug susceptibility patterns for circulating influenza virus strains when deciding whether to use XOFLUZA.
Contraindications
XOFLUZA is contraindicated in patients with a history of hypersensitivity to baloxavir marboxil or any of its ingredients. Serious allergic reactions have included anaphylaxis, angioedema, urticaria, and erythema multiforme.
Warnings and Precautions
Hypersensitivity: Cases of anaphylaxis, urticaria, angioedema, and erythema multiforme have been reported in postmarketing experience with XOFLUZA. Appropriate treatment should be instituted if an allergic-like reaction occurs or is suspected.
Increased Incidence of Treatment-Emergent Resistance in Patients Less Than 5 Years of Age: XOFLUZA is not indicated in patients less than 5 years of age due to increased incidence of treatment-emergent resistance in this age group. In clinical trials, the incidence of virus with treatment-emergent substitutions associated with reduced susceptibility to baloxavir (resistance) was higher in pediatric subjects younger than 5 years of age (43%, 36/83) than in pediatric subjects ≥5 years to <12 years of age (16%, 19/117) or subjects ≥12 years of age (7%, 60/842). The potential for transmission of resistant strains in the community has not been determined.
Risk of bacterial Infections: There is no evidence of the efficacy of XOFLUZA in any illness caused by pathogens other than influenza viruses. Serious bacterial infections may begin with influenza-like symptoms or may coexist with, or occur as, a complication of influenza. XOFLUZA has not been shown to prevent such complications. Prescribers should be alert to potential secondary bacterial infections and treat them as appropriate.
Adverse Reactions
Drug Interactions
Polyvalent cations: Coadministration with polyvalent cation-containing products may decrease plasma concentrations of baloxavir, which may reduce XOFLUZA efficacy. Avoid coadministration of XOFLUZA with dairy products, calcium-fortified beverages, polyvalent cation-containing laxatives, antacids, or oral supplements (e.g., calcium, iron, magnesium, selenium, or zinc).
Vaccines: The concurrent use of XOFLUZA with intranasal live attenuated influenza vaccine (LAIV) has not been evaluated. Concurrent administration of antiviral drugs may inhibit viral replication of LAIV and, thereby, decrease the effectiveness of LAIV vaccination. Interactions between inactivated influenza vaccines and XOFLUZA have not been evaluated.
For additional Important Safety Information, please see the XOFLUZA full Prescribing Information.
You are encouraged to report side effects to Genentech by calling 1-888-835-2555 or to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088.
XOFLUZA. Prescribing information. Genentech USA, Inc.
XOFLUZA. Prescribing information. Genentech USA, Inc.
Baker J, Block SL, Matharu B, et al. Baloxavir marboxil single-dose treatment in influenza-infected children: a randomized, double-blind, active controlled phase 3 safety and efficacy trial (miniSTONE-2). Pediatr Infect Dis J. 2020;39(8):700-705. doi:10.1097/INF.0000000000002747
Baker J, Block SL, Matharu B, et al. Baloxavir marboxil single-dose treatment in influenza-infected children: a randomized, double-blind, active controlled phase 3 safety and efficacy trial (miniSTONE-2). Pediatr Infect Dis J. 2020;39(8):700-705. doi:10.1097/INF.0000000000002747
TAMIFLU. Prescribing information. Genentech USA, Inc.; 2019.
TAMIFLU. Prescribing information. Genentech USA, Inc.; 2019.
Hayden FG, Sugaya N, Hirotsu N, et al; Baloxavir Marboxil Investigators Group. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N Engl J Med. 2018;379(10):913-923.
Hayden FG, Sugaya N, Hirotsu N, et al; Baloxavir Marboxil Investigators Group. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N Engl J Med. 2018;379(10):913-923.
People at higher risk of flu complications. Centers for Disease Control and Prevention (CDC). Accessed May 18, 2022. https://www.cdc.gov/flu/highrisk/index.htm
People at higher risk of flu complications. Centers for Disease Control and Prevention (CDC). Accessed May 18, 2022. https://www.cdc.gov/flu/highrisk/index.htm
National Diabetes Statistics Report. CDC. Accessed May 18, 2022. https://www.cdc.gov/diabetes/data/statistics-report/index.html
National Diabetes Statistics Report. CDC. Accessed May 18, 2022. https://www.cdc.gov/diabetes/data/statistics-report/index.html
Most recent national asthma data. CDC. Accessed May 18, 2022. https://www.cdc.gov/asthma/most_recent_national_asthma_data.htm
Most recent national asthma data. CDC. Accessed May 18, 2022. https://www.cdc.gov/asthma/most_recent_national_asthma_data.htm
Basics about COPD. CDC. Accessed May 18, 2022. https://www.cdc.gov/copd/basics-about.html
Basics about COPD. CDC. Accessed May 18, 2022. https://www.cdc.gov/copd/basics-about.html
Heart disease. CDC. Accessed May 18, 2022. https://www.cdc.gov/nchs/fastats/heart-disease.htm
Heart disease. CDC. Accessed May 18, 2022. https://www.cdc.gov/nchs/fastats/heart-disease.htm
Flu vaccination coverage, United States, 2021-22 influenza season. CDC. Accessed August 9, 2022. https://www.cdc.gov/flu/fluvaxview/coverage-2021estimates.htm
Flu vaccination coverage, United States, 2021-22 influenza season. CDC. Accessed August 9, 2022. https://www.cdc.gov/flu/fluvaxview/coverage-2021estimates.htm
Ison MG. Portsmouth high-risk adolescent and adult outpatients with uncomplicated influenza (CAPTONSE-2): a randomised, placebo-controlled, phase 3 trial. Lancet Infect Dis. Published online June 8, 2020. doi:10.1016/S1473-3099(20)30004-9
Ison MG. Portsmouth high-risk adolescent and adult outpatients with uncomplicated influenza (CAPTONSE-2): a randomised, placebo-controlled, phase 3 trial. Lancet Infect Dis. Published online June 8, 2020. doi:10.1016/S1473-3099(20)30004-9
Supplement to: Ison MG, Portsmouth S, Yoshida Y, et al. Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial. Lancet Infect Dis. 2020;20(10)suppl:S8-S10.
Supplement to: Ison MG, Portsmouth S, Yoshida Y, et al. Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial. Lancet Infect Dis. 2020;20(10)suppl:S8-S10.
Clinical signs and symptoms of influenza. CDC. Accessed May 18, 2022. https://www.cdc.gov/flu/professionals/acip/clinical.htm
Clinical signs and symptoms of influenza. CDC. Accessed May 18, 2022. https://www.cdc.gov/flu/professionals/acip/clinical.htm
Ikematsu H, Hayden FG, Kawaguchi K, et al. Baloxavir marboxil for prophylaxis against influenza in household contacts. N Engl J Med. 2020;383(4):309-320. doi:10.1056/NEJMoa1915341
Ikematsu H, Hayden FG, Kawaguchi K, et al. Baloxavir marboxil for prophylaxis against influenza in household contacts. N Engl J Med. 2020;383(4):309-320. doi:10.1056/NEJMoa1915341
Estimated influenza illnesses, medical visits, hospitalizations, and deaths in the United States—2021-2022 influenza season. CDC. Accessed August 1, 2022. https://www.cdc.gov/flu/about/burden/preliminary-in-season-estimates.htm
Estimated influenza illnesses, medical visits, hospitalizations, and deaths in the United States—2021-2022 influenza season. CDC. Accessed August 1, 2022. https://www.cdc.gov/flu/about/burden/preliminary-in-season-estimates.htm
COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Updated May 13, 2022. Accessed May 18, 2022. https://files.covid19treatmentguidelines.nih.gov/guidelines/covid19treatmentguidelines.pdf
COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Updated May 13, 2022. Accessed May 18, 2022. https://files.covid19treatmentguidelines.nih.gov/guidelines/covid19treatmentguidelines.pdf
What is the difference between influenza (flu) and COVID-19? CDC. Accessed May 18, 2022. https://www.cdc.gov/flu/symptoms/flu-vs-covid19.htm
What is the difference between influenza (flu) and COVID-19? CDC. Accessed May 18, 2022. https://www.cdc.gov/flu/symptoms/flu-vs-covid19.htm
Cold versus flu. CDC. Accessed May 18, 2022. https://www.cdc.gov/flu/symptoms/coldflu.htm
Cold versus flu. CDC. Accessed May 18, 2022. https://www.cdc.gov/flu/symptoms/coldflu.htm
COVID data tracker. CDC. Accessed May 18, 2022. https://covid.cdc.gov/covid-data-tracker/#cases_ casesinlast7days
COVID data tracker. CDC. Accessed May 18, 2022. https://covid.cdc.gov/covid-data-tracker/#cases_ casesinlast7days
Common colds: protect yourself and others. CDC. Accessed May 18, 2022. https://www.cdc.gov/features/rhinoviruses/index.html
Common colds: protect yourself and others. CDC. Accessed May 18, 2022. https://www.cdc.gov/features/rhinoviruses/index.html
Lessler J, Reich NG, Brookmeyer R, Perl TM, Nelson KE, Cummings DAT. Incubation periods of acute respiratory viral infections: a systematic review. Lancet Infect Dis. 2009;9(5):291-300. doi:10.1016/s1473-3099(09)70069-6
Lessler J, Reich NG, Brookmeyer R, Perl TM, Nelson KE, Cummings DAT. Incubation periods of acute respiratory viral infections: a systematic review. Lancet Infect Dis. 2009;9(5):291-300. doi:10.1016/s1473-3099(09)70069-6
Symptoms of COVID-19. CDC. Updated March 22, 2022. Accessed May 18, 2022. https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html
Symptoms of COVID-19. CDC. Updated March 22, 2022. Accessed May 18, 2022. https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html
Key facts about influenza (flu). CDC. Accessed May 18, 2022. https://www.cdc.gov/flu/about/keyfacts.htm
Key facts about influenza (flu). CDC. Accessed May 18, 2022. https://www.cdc.gov/flu/about/keyfacts.htm
Influenza antiviral medications: summary for clinicians. CDC. Accessed May 18, 2022. https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm#Table1
Influenza antiviral medications: summary for clinicians. CDC. Accessed May 18, 2022. https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm#Table1
Samji T. Influenza A: understanding the viral life cycle. Yale J Biol Med. 2009;82(4):153-159.
Samji T. Influenza A: understanding the viral life cycle. Yale J Biol Med. 2009;82(4):153-159.
De Clercq E, Li G. Approved antiviral drugs over the past 50 years. Clin Microbiol Rev. 2016;29(3):695-747.
De Clercq E, Li G. Approved antiviral drugs over the past 50 years. Clin Microbiol Rev. 2016;29(3):695-747.
Fiore AE, Fry A, Shay D, et al. Antiviral agents for the treatment and chemoprophylaxis of influenza—recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2011;60(1):1-24.
Fiore AE, Fry A, Shay D, et al. Antiviral agents for the treatment and chemoprophylaxis of influenza—recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2011;60(1):1-24.
von Itzstein M. The war against influenza: discovery and development of sialidase inhibitors. Nat Rev Drug Discov. 2007;6(12):967-974. doi:10.1038/nrd2400
von Itzstein M. The war against influenza: discovery and development of sialidase inhibitors. Nat Rev Drug Discov. 2007;6(12):967-974. doi:10.1038/nrd2400
Data on File. Genentech. 2022.
Data on File. Genentech. 2022.
The information contained in this section of the site is intended for US healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.